Avidity Biosciences, Inc.RNAEarnings & Financial Report
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
Revenue
$2.0M
Gross Profit
N/A
Operating Profit
$-82.6M
Net Profit
$-70.8M
Gross Margin
N/A
Operating Margin
-4040.4%
Net Margin
-3461.8%
YoY Growth
-11.7%
EPS
$-0.65
Avidity Biosciences, Inc. Q2 FY2024 Financial Summary
Avidity Biosciences, Inc. reported revenue of $2.0M (down 11.7% YoY) for Q2 FY2024, with a net profit of $-70.8M (down 50.5% YoY) (-3461.8% margin).
Key Financial Metrics
| Total Revenue | $2.0M |
|---|---|
| Net Profit | $-70.8M |
| Gross Margin | N/A |
| Operating Margin | -4040.4% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
Avidity Biosciences, Inc. Q2 FY2024 revenue of $2.0M breaks down across 2 segments, led by Research Collaboration License Agreement And Securities Purchase Agreement With BMS at $2.0M (97.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Research Collaboration License Agreement And Securities Purchase Agreement With BMS | $2.0M | 97.8% |
| Other | $45.0K | 2.2% |
Avidity Biosciences, Inc. Revenue by Segment — Quarterly Trend
Avidity Biosciences, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Research Collaboration License Agreement And Securities Purchase Agreement With BMS and Other) has evolved quarter over quarter.
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|
| Research Collaboration License Agreement And Securities Purchase Agreement With BMS | — | $3.8M | $1.6M | $3.1M |
Avidity Biosciences, Inc. Annual Revenue by Year
Avidity Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $10.9M).
| Year | Annual Revenue |
|---|---|
| 2024 | $10.9M |
| 2023 | $9.6M |
| 2022 | $9.2M |
Avidity Biosciences, Inc. Quarterly Revenue & Net Profit History
Avidity Biosciences, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $12.5M | +434.0% | $-174.4M | -1398.3% |
| Q2 FY2025 | $3.8M | +88.1% | $-157.3M | -4089.3% |
| Q1 FY2025 | $1.6M | -55.6% | $-115.8M | -7360.0% |
| Q4 FY2024 | $3.0M | +35.6% | $-102.3M | -3439.5% |
| Q3 FY2024 | $2.3M | -17.1% | $-80.4M | -3441.7% |
| Q2 FY2024 | $2.0M | -11.7% | $-70.8M | -3461.8% |
| Q1 FY2024 | $3.5M | +58.7% | $-68.9M | -1943.4% |
| Q4 FY2023 | $2.2M | -20.8% | $-60.4M | -2756.2% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $3.5M | $2.0M | $2.3M | $3.0M | $1.6M | $3.8M | $12.5M |
| YoY Growth | -20.8% | 58.7% | -11.7% | -17.1% | 35.6% | -55.6% | 88.1% | 434.0% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $628.6M | $951.5M | $1.35B | $1.64B | $1.56B | $1.46B | $1.37B | $2.13B |
| Liabilities | $127.8M | $120.6M | $126.4M | $137.4M | $138.9M | $130.4M | $176.3M | $247.9M |
| Equity | $500.8M | $830.9M | $1.22B | $1.50B | $1.42B | $1.33B | $1.19B | $1.89B |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $16.5M | $-70.4M | $-65.0M | $-65.6M | $-99.9M | $-124.8M | $-199.7M | $-156.2M |